Novartis Presents Data on Delayed Diabetes Drug Galvus

Drug Industry Daily
Patients with uncontrolled Type 2 diabetes treated with metformin were four times more likely to achieve recommended blood sugar control levels by adding Galvus to their treatment regimen compared to those who added a placebo, according to new clinical data Novartis announced this week.

To View This Article:


Subscribe To Drug Industry Daily